T cell chemokine receptor expression in human Th1- and Th2-associated diseases

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 6, 2000, Pages 451-456

  Campbell, J Darren ^a   Hayglass, Kent T ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Atopy; Chemokine receptors; Chemokines; Multiple sclerosis; Rheumatoid arthritis; T cells

Indexed keywords

CHEMOKINE RECEPTOR;

ASTHMA; AUTOIMMUNE DISEASE; HAY FEVER; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH2 CELL;

ARTHRITIS, RHEUMATOID; ASTHMA; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE; RHINITIS, ALLERGIC, SEASONAL; TH1 CELLS; TH2 CELLS;

EID: 0034567697     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. ANNUNZIATO F., COSMI L., GALLI G., BELTRAME C., ROMAGNANI P., MANETTI R., ROMAGNANI S. and MAGGI E. (1999): Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J. Leukoc. Biol., 65, 691-699.
2. ARENBERG D. A., KUNKEL S. C., POLVERINI P. J., MORRIS S. B., BURDICK M. D., GLASS M. C., TAUB D. T., IANETTONI M. D., WHYTE R. I. and STRIETER R. M. (1996): Interferon-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med., 184, 981-992.
3. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA, 96, 6873-6878.
4. BENNETTS B. H., TEUTSCH S. M., BUHLER M. M., HEARD R. N. S. and STEWART G. J. (1997): The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol., 58, 52-59.
5. BONECCHI R., BIANCHI G., BORDIGNON P. P., D'AMBROSIO D., LANG R., BORSATTI A., SOZZANI S., ALLAVENA P., GRAY P. A., MANTOVANI A. and SINIGAGLIA F. (1998): Differential expression of chemokine receptors and chemotactic responsiveness of type 1 helper cells (Th1s) and Th2s. J. Exp. Med., 187, 129-134.
6. D'AMBROSIO D., IELLEM A., BONECCHI R., MAZZEO D., SOZZANI S., MANTOVANI A. and SINIGAGLIA F. (1998): Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J. Immunol., 161, 5111-5115.
7. DURHAM S. R. (1998): Mechanisms of mucosal inflammation in the nose and lungs. Clin. Exp. Allergy, 28 (suppl. 2), 11-16.
8. GALLI G., CHANTRY D., ANNUNZIATO F., ROMAGNANI P., COSMI L., LAZZERI E., MANETTI R., MAGGI E., GRAY P. W. and ROMANGNANI S. (2000): Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 chemokines. Eur. J. Immunol., 30, 204-210.
9. GANGUR V., SIMONS F. E. R. and HAYGLASS K. T. (1998): Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-γ over IL-4 responses. FASEB J., 12, 705-713.
10. GARRED P., MADSEN H. O., PETERSEN J., MARQUART H., HANSEN T. M., SORENSEN S. F., VOLCK B., SVEJGAARD A. and ANDERSEN V. (1998): CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol., 25, 1462-1465.
11. GERBER B. O., ZANNI M. P., UGUCCIONI M., LOETSCHER M., MACKAY C. R., PICHLER W. J., YAWALKAR N., BAGGIOLINI M. and MOSER B. (1997): Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr. Biol., 7, 836-843.
12. GHAFFER O., CHRISTODOULOPOULOS P. and HAMID Q. (2000): Cellular sources of chemokines in allergic diseases. In Rothenberg M. E.: Chemokines in allergic disease. Marcel Dekker, New York, 403-424.
13. GOMEZ-REINO J. J., PABLOS J. L., CARREIRA P. E., SANTIAGO B., SERRANO L., VICARIO J. L., BALSA A., FIGUEROA M. and DE JUAN M. (1999): Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum., 42, 989-992.
14. GU L., TSENG S., HORNER R. M., TAM C., LODA M. and ROLLINS B. J. (2000): Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature, 404, 407-411.
15. GUTIERREZ-RAMOS J. C., LLOYD C. and GONZALO J. A. (1999): Eotaxin: from an eosinphilic chemokine to a major regulator of allergic reactions. Immunol. Today, 20, 500-504.
16. JINQUAN T., QUAN S., FEILI G., LARSEN C. G. and THESTRUP-PEDERSEN K. (1999): Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J. Immunol., 162, 4285-4292.
17. KARPUS W. J., LUKACS N. W., KENNEDY K. J., SMITH W. S., HURST S. D. and BARRETT T. A. (1997): Differential CC chemokine-induced enhancement of T helper cell cytosine production. J. Immunol., 158, 4129-4136.
18. +) T cells and eosinphils in allergy and asthma. Am. Rev. Respir. Dis., 145, 22-26.
19. KUSABA M., HONDA J., FUKUDA T. and OIZUMI K. (1998): Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J. Rheumatol., 25, 1466-1471.
20. + T cells in the pathogenesis of organ-specfic autoimmune diseases. Immunol. Today, 16, 34-38.
21. LIU R., PAXTON W. A., CHOE S., CERADINI D., MARTIN S. R., HORUK R., MACDONALD M. E., STUHLMANN H., KOUP R. A. and LANDAU N. R. (1996): Homozygous defect in HIV-1 co-receptor accounts for resistance for some multiple-exposed individuals to HIV-1 infection. Cell, 86, 367-377.
22. LLOYD C. M., DELANEY T., NGUYEN T., TIAN J., MARTINEZ-A. C., COYLE A. J. and GUTIERREZ-RAMOS J.-C. (2000): CC chemokine receptor (CCR) 3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med., 191, 265-273.
23. LOETSCHER P., UGUCCIONI M., BORDOLI L., BAGGIOLINI M., MOSER B., CHIZZOLINI C. and DAYER J.-M. (1998): CCR5 is characteristic of Th1 lymphocytes. Nature, 391, 344-345.
24. LU C. Z., JENSEN M. A. and ARNASON B. G. W. (1993): Interferon gamma and interleukin 4-secreting cells in multiple sclerosis. J. Neuroimmunol., 46, 123-128.
25. MACK M., BRUHL H., GRUBER R., JAEGER C., CIHAK J., EITER V., PLACHY J., STANGASSINGER M., UHLIG K., SCHATTENKIRCHNER M. and SCHLONDORFF D. (1999): Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum., 42, 981-988.
26. MAIONE T. E., GRAY G. S., PETRO J. and HUNT A. J. (1990): Inhibition of angiogenesis by recombinant platelet factor 4 and related peptides. Science, 247, 77-79.
27. MARTIN R., MCFARLAND H. F. and MCFARLIN D. E. (1992): Immunological aspects of demyelinating diseases. Annu. Rev. Immunol., 10, 153-187.
28. MINSHALL E. M., CAMERON L., LAVGNE F., LEUNG D. Y. M., HAMILOS D., GARCIA-ZEPADA E. A., ROTHENBERG M., LUSTER A. D. and HAMID Q. (1997): Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am. J. Respir. Cell Mol. Biol., 17, 683-690.
29. NAKAMURA H., WEISS S. T., ISRAEL E., LUSTER A. D., DRAZEN J. M. and LILLY C. M. (1999): Eotaxin and impaired lung function in asthma. Am. J. Respir. Crit. Care Med., 160, 1952-1956.
30. NICKEL R., BECK L. A., STELLATO C. and SCHLEIMER R. P. (1999): Chemokines and allergic disease. J. Allergy Clin. Immunol., 104, 723-742.
31. ODUM N., BREGENHOLT S., ERIKSEN K. W., SKOV S., RYDER L. P., BENDTZEN K., VAN NEERVEN R. J. J., SVEJGAARD A. and GARRED P. (1999): The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. Tissue Antigens. 54, 572-577.
32. PANAYI G. S. (1997): T cell-dependent pathways in rheumatoid arthritis. Curr. Opin. Rheumatol., 9, 236-240.
33. PANITCH H. S., HIRSCH R. L., HALEY A. S. and JOHNSON K. P. (1987): Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1, 893-895.
34. PELED A., GONZALO J. A., LLOYD C. and GUTIERREZ-RAMOS J.-C. (1998): The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation. Blood, 91, 1909-1916.
35. QIN S., ROTTMAN J. B., MYERS P., KASSAM N., WEINBLATT M., LOETSCHER M., KOCH A. E., MOSER B. and MACKAY C. R. (1998): The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest., 101, 746-754.
36. RANKIN S. M., CONROY D. M. and WILLIAMS T. J. (2000): Eotaxin and eosinophil recruitment: implications for human disease. Mol. Med. Today, 6, 20-27.
37. ROMAGNANI P., DE PAULIS A., BELTRAME C., ANNUNZIATO F., DENTE V., MAGGI E., ROMAGNANI S. and MARONI G. (1999): Tryptase chymase double positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3 binding chemokines. Am. J. Pathol., 155, 1195-1204.
38. SALLUSTO F., LENIG D., MACKAY C. R. and LANZAVECCHIA A. (1998): Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med., 187, 875-883.
39. SALLUSTO F., MACKAY C. R. and LANZAVECCHIA A. (1997): Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science, 277, 2005-2007.
40. SAMSON M., LIBERT F., DORANZ B. J., RUCKER J., LIESNARD C., FARBER C. M., SARAGOSTI S., LAPOUMEROULIE C., COGNAUX J., FORCEILLE C., MUYLDERMANS G., VERHOFSTEDE C., BURTONBOY G., GEORGES M., IMAI T., RANA S., Yi Y., SMYTH R. J., COLLMAN R. G., DOMS R. W., VASSART G. and PARMENTIER M. (1996): Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature, 382, 722-725.
41. SELLEBJERG F., MADSEN H. O., JENSEN C. V., JENSEN J. and GARRED P. (2000): CCR5 delta 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol., 102, 98-106.
42. SORENSEN T. L., TANI M., PIERCE V., LUCCHINETTI C., FOLCIK V. A., QIN S., ROTTMAN J., SELLEBJERG F., STRIETER R. M., FREDERIKSEN J. L. and RANSOHOFF R. M. (1999): Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest., 103, 807-815.
43. + interferon-γ and tumor necrosis factor-α secreting T lymphocytes in multiple sclerosis patients. Ann. Neurol., 47, 269-273.
44. + T lymphocytes into inflammed joints of rheumatoid arthritis. Int. Immunol., 11, 553-559.
45. TRAPP B., PETERSON J., RANSOHOFF R. M., RUDICK R., MORK S. and BO L. (1998): Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med., 338, 278-290.
46. YAWALKAR N., UGUCCIONI M., SCHARER J., BRAUNWALDER J., KARLEN S., DEWALD B., BRAATHEN L. R. and BAGGIOLINI M. (1999): Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J. Invest. Dermatol., 113, 43-48.
47. YING S., ROBINSON D. S., MENG Q., ROTTMAN J., KENNEDY R., RINGLER D. J., MACKAY C. R., DAUGHERTY B. L., SPRINGER M. S., DURHAM S. R., WILLIAMS T. J. and KAY A. B. (1997): Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol., 27, 3507-3516.